Xue Sheng, Liu Dacheng, Zhu Wenjie, Su Zhe, Zhang Liwei, Zhou Changyong, Li Peifeng
Institute for Translational Medicine, College of Medicine, Qingdao University, Qingdao, China.
The Affiliated Hospital of Qingdao University, Qingdao University, Qingdao, China.
Front Physiol. 2019 Feb 18;10:123. doi: 10.3389/fphys.2019.00123. eCollection 2019.
Ischemic heart disease including myocardial infarction (MI) is a major cause of mortality and morbidity worldwide. In order to manage the acute myocardial infarction (AMI) outbreaks, novel biomarkers for risk prediction are needed. Recent studies have shown that circulating microRNAs (miRNAs) are promising biomarkers for cardiovascular diseases prediction. This study aimed to determine the possibility of circulating miRNAs used as biomarkers for AMI. The dynamic expression levels of miRNAs were examined before and after percutaneous coronary intervention (PCI) in patients. Circulating miR-17-5p, miR-126-5p, and miR-145-3p were selected and validated in 29 patients with AMI and 21 matched controls by quantitative real-time PCR. The expression levels of plasma miR-17-5p, miR-126-5p, and miR-145-3p were significantly increased in AMI patients. Receiver Operating Characteristic (ROC) analysis indicated that miR-17-5p, miR-126-5p, and miR-145-3p showed considerable diagnostic efficiency for AMI. Furthermore, we demonstrated that the combination of these three miRNAs managed to provide more accurate diagnosing of AMI.
包括心肌梗死(MI)在内的缺血性心脏病是全球范围内导致死亡和发病的主要原因。为了应对急性心肌梗死(AMI)的爆发,需要用于风险预测的新型生物标志物。最近的研究表明,循环微RNA(miRNA)是用于心血管疾病预测的有前景的生物标志物。本研究旨在确定循环miRNA用作AMI生物标志物的可能性。检测了患者经皮冠状动脉介入治疗(PCI)前后miRNA的动态表达水平。通过定量实时PCR在29例AMI患者和21例匹配对照中对循环miR-17-5p、miR-126-5p和miR-145-3p进行了选择和验证。AMI患者血浆miR-17-5p、miR-126-5p和miR-145-3p的表达水平显著升高。受试者工作特征(ROC)分析表明,miR-17-5p、miR-126-5p和miR-145-3p对AMI具有相当高的诊断效率。此外,我们证明这三种miRNA的组合能够更准确地诊断AMI。